Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.
By M. George, Sarah H. Lisanby, D. Avery, W. McDonald, Valerie L. Durkalski, M. Pavlicova, B. Anderson, Z. Nahas, Peter Bulow, P. Zarkowski and 3 more. Archives of General Psychiatry, 2010
1,054 citations recorded by the source corpus.
Subfields: Anesthesiology and Pain Medicine, Cognitive Neuroscience, Neurology
View Paper: https://www.semanticscholar.org/paper/483c38773a88ab0293dc2ac7fb0934c88a69ea32
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cognitive Neuroscience
- B. Casey
- Amit Etkin
- P. Moseley
- A. Schatzberg
- Andrew T. Drysdale
- Sarah H. Lisanby
- Stephan F. Taylor
- Anthony A. Grace
In Neurology
Citations in the corpus
- Neuroscience and Biobehavioral Reviews Auditory Verbal Hallucinations as Atypical Inner Speech Monitoring, and the Potential of Neurostimulation as a Treatment Option (positive): “Perhaps most famously, the observation that under-activation of the left dorsolateral prefrontal cortex often coincides with clinical depression led to the use of high-frequency rTMS over this area, and there is evidence that it may be an effective treatment option (George et al., 2010, 1995).”
- Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. (2021, methodology): “We recruited individuals for this study who had a primary diagnosis of major depressive disorder, were currently experiencing a moderate to severe depressive episode (scores $20 on the 17-item Hamilton Depression Rating Scale [HAM-D] and the Montgomery-Åsberg Depression Rating Scale [MADRS]) (6, 28)”
- Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression (2014, background): “Still, most treatment-refractory patients will not achieve full remission (3), and recent metanalyses indicate that the effect size (Cohen’s d) lies in the 0.”
- Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. (2017, background): “…magnetic stimulation device package insert as well as in the US Food and Drug Administration (FDA) 510k application material. b In the study by George et al,10 patients underwent head magnetic resonance imaging with fiducials (vitamin E capsules), which resulted in 33.2% of patients having…”
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). (2014, neutral): “The North American multicenter studies (O’Reardon et al., 2007b; George et al., 2010) are remarkable for the large number of patients included (301 and 199), the control of drug treatment, and the design with parallel arms of active condition versus sham condition.”
- Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines (2020, positive): “, 2009) including large-scale clinical trials of rTMS for depression (Blumberger et al., 2018; George et al., 2010).”
- Dopamine System Dysregulation in Major Depressive Disorders (2017, background): “…for MDD such as antidepressants (Mayberg et al., 2000), electroconvulsive therapy (Nobler et al., 2001), transcranial magnetic stimulation (George et al., 2010), and vagus nerve stimulation (Nahas et al., 2007) cause a return to normal levels of activity of the PFC that correlate with…”